These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33732241)

  • 1. A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker.
    Gillis A; Ben Yaacov A; Agur Z
    Front Immunol; 2021; 12():616881. PubMed ID: 33732241
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab.
    Hotchkiss RS; Colston E; Yende S; Crouser ED; Martin GS; Albertson T; Bartz RR; Brakenridge SC; Delano MJ; Park PK; Donnino MW; Tidswell M; Mayr FB; Angus DC; Coopersmith CM; Moldawer LL; Catlett IM; Girgis IG; Ye J; Grasela DM
    Intensive Care Med; 2019 Oct; 45(10):1360-1371. PubMed ID: 31576433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage.
    Fukuda R; Sugawara S; Kondo Y
    Intern Med; 2020 Sep; 59(18):2245-2248. PubMed ID: 32522918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alleviation of exhaustion-induced immunosuppression and sepsis by immune checkpoint blockers sequentially administered with antibiotics-analysis of a new mathematical model.
    Gillis A; Beil M; Halevi-Tobias K; van Heerden PV; Sviri S; Agur Z
    Intensive Care Med Exp; 2019 Jun; 7(1):32. PubMed ID: 31187301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based rationale for low dose nivolumab in critically ill patients with sepsis-induced immunosuppression.
    van den Haak DAC; Otten LS; Koenen HJPM; Smeets RL; Piet B; Pickkers P; Kox M; Ter Heine R
    Clin Transl Sci; 2023 Jun; 16(6):978-986. PubMed ID: 37002646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study.
    Watanabe E; Nishida O; Kakihana Y; Odani M; Okamura T; Harada T; Oda S
    Shock; 2020 Jun; 53(6):686-694. PubMed ID: 31513050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
    Brunkhorst FM; Oppert M; Marx G; Bloos F; Ludewig K; Putensen C; Nierhaus A; Jaschinski U; Meier-Hellmann A; Weyland A; Gründling M; Moerer O; Riessen R; Seibel A; Ragaller M; Büchler MW; John S; Bach F; Spies C; Reill L; Fritz H; Kiehntopf M; Kuhnt E; Bogatsch H; Engel C; Loeffler M; Kollef MH; Reinhart K; Welte T;
    JAMA; 2012 Jun; 307(22):2390-9. PubMed ID: 22692171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with nivolumab in a patient with lung adenocarcinoma complicated by pulmonary aspergilloma.
    Furuya N; Kojima K; Marushima H; Kakinuma K; Tsunoda A; Koda E; Tsuruoka H; Nishida K; Inoue T; Saji H; Mineshita M
    Thorac Cancer; 2020 Nov; 11(11):3391-3395. PubMed ID: 32941695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
    Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
    Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment-related Skin Toxicity Caused by Programmed Death-1 Inhibitor Nivolumab: 
A Case Report].
    Gao L; Yu Y; Lu S
    Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):250-254. PubMed ID: 31014445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
    Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
    Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
    Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.
    Gane E; Verdon DJ; Brooks AE; Gaggar A; Nguyen AH; Subramanian GM; Schwabe C; Dunbar PR
    J Hepatol; 2019 Nov; 71(5):900-907. PubMed ID: 31306680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
    Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
    Front Immunol; 2020; 11():895. PubMed ID: 32528470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
    Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
    Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.
    Sun D; Liu D; Liu Q; Hou H
    Cancer Biol Ther; 2020 Dec; 21(12):1097-1104. PubMed ID: 33151119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.